Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Feb 23, 2011


Raymond Woosley, president, CEO and board chairman of the Critical Path Institute, will retire from his position as president on Jan. 31, 2012. The institute's board is currently recruiting for someone to fill this post.

Woosley has said he plans to remain involved in C-Path. After his retirement as president, he will continue serving on the board of directors and leading C-Path’s Arizona Center for Education and Research on Therapeutics.

Woosley launched C-Path in 2005 to provide independent guidance to the US Food and Drug Administration and industry on drug development issues, so that new treatments can enter the market quickly. Under Woosley's leadership, C-Path currently employs more than 50 scientists. The institute has expanded beyond its headquarters in Arizona to operating offices in Rockville, Md., to be closer to the FDA and policy issues in Washington, DC.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.